Imugene Ltd has released a press release.
Imugene onCARlytics Doses First Patient in IV Combination
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
- Imugene and Kincell Bio Announce Strategic Partnership
- Bile Tract Cancer Study Opens after MAST High Dose Clearance
- VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
- Oncolytic Virotherapy CF33 Patent Granted in China
Later from Imugene
- First patient dosed in Phase 1 bile tract cancer trial
- Three Complete Responses in Azer-Cel Phase 1b Trial
- Imugene Receives Orphan Drug Designation for VAXINIA
- Complete Response in MAST Study Maintained Over Two Years
- Imugene Opens First Australian Site for azer-cel Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene